福元医药：左甲状腺素钠片获得药品注册证书

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Levothyroxine Sodium Tablets, indicating approval for production [1] Group 1 - The Levothyroxine Sodium Tablets are approved in a specification of 100μg (based on Levothyroxine Sodium) [1] - The drug was developed by Merck and was first approved for marketing in France in June 1980 [1] - The company received the acceptance notice for the application on March 27, 2024, and has invested a total of RMB 7.57 million in research and development for this drug as of the announcement date (unaudited) [1]